Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease Read more
The stage is set for 2 rate cuts this year, but investors need to be careful adding more exposure to the stock market, JPMorgan strategy chief says Read more